Related Experiment Video
Updated: Aug 9, 2026

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
Genetic prodrug activation therapy
1ICRF Molecular Oncology Unit, Imperial College of Medicine, Hammersmith Hospital, London, UK. a.rigg@icrf.icnet.uk
Abstract:
Genetic prodrug activation therapy shows promise as a therapeutic option for the treatment of cancer as well as a variety of other diseases. It involves the insertion of a gene encoding a drug-metabolizing enzyme into cells and the systemic administration of a prodrug. The prodrug is converted to a cytotoxic agent by the action of the expressed enzyme. To ensure that the enzyme is only expressed in the targeted subset of cells, the transcriptional apparatus of a gene that is unique to this subset is used to regulate the gene encoding the drug-metabolizing enzyme. As with all types of gene therapy, one of the major obstacles to successful clinical treatment is the development of safe and effective gene delivery systems.
Insights
Genetic prodrug activation therapy uses gene therapy to convert inactive drugs into cancer-killing agents specifically in targeted cells. Developing safe gene delivery systems remains a key challenge for this promising treatment.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Therapeutics
Background:
- Genetic prodrug activation therapy offers a novel approach for treating various diseases, including cancer.
- This therapy involves introducing a gene for a drug-metabolizing enzyme into cells.
- The enzyme then converts a systemically administered prodrug into a cytotoxic agent.
Purpose of the Study:
- To explore the potential of genetic prodrug activation therapy.
- To highlight the mechanism of targeted enzyme expression for localized drug activation.
- To identify challenges in gene delivery for clinical application.
Main Methods:
- Utilizing transcriptional regulation of a gene unique to target cells to control enzyme expression.
- Employing gene therapy principles for localized prodrug conversion.
- Systemic administration of a prodrug for activation within targeted cells.
Main Results:
- Demonstrated the principle of targeted enzyme expression for specific prodrug activation.
- Showcased the potential for localized cytotoxic agent generation.
- Identified gene delivery systems as a critical hurdle for clinical translation.
Conclusions:
- Genetic prodrug activation therapy is a promising strategy for cancer and other diseases.
- Precise control over enzyme expression in target cells is achievable.
- Advancements in safe and effective gene delivery are crucial for clinical success.
Related Concept Videos
Gene Therapy
Gene Therapy
Prodrugs
Prodrugs help overcome...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets

